Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Phase 3 weight management (ChiCTR1900023428)

Phase 3 weight management (ChiCTR1900023428)

Beinaglutide · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Beinaglutide
Population
obesity
Phase
3
Participants
282
Duration
16 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
0.2 mg TIDobesity china16282——−6.0 % vs −2.4 %
estimand not specified
—5.9 vs 0.7—49.3 vs 7.1———press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (3)
  • 0.2 mg TID · weight_unsp · publication
    Mean body weight change from baseline to week 16 was -6.0% and -2.4% in the beinaglutide (n = 282) and placebo (n = 138) groups
  • 0.2 mg TID · nausea · publication
    Nausea (transient and mild-to-moderate) was the most common adverse event in the beinaglutide group (49.3% vs. 7.1% [placebo]).
  • 0.2 mg TID · ae_dc · publication
    More patients receiving beinaglutide discontinued treatment because of adverse events (5.9% vs. 0.7% [placebo]).

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Phase 3 weight management (ChiCTR1900023428). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-3-weight-management/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.